Natco Pharma has rallied almost 6% to Rs 450 in opening deals after the Hyderabad-based company won a cancer drug case against multinational pharma major Bayer Corporation.
“The Intellectual Property Appellate Board (IPAB) has upheld the Compulsory License (CL) issued by the Controller of Patent to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation,” the Business Standard report suggests.
“The Appellate Board however made changes in the CL order to the extend that the royalty payment to Bayer has been increased from 6% to 7%. The Board also imposed a penalty on Natco for submitting false statement,” added report.
The order will pave the way for reduction in the prices of costly life saving drugs.The stock opened at Rs 449 and touched high of Rs 475 on NSE. A combined around 18,000 shares have changed hands on the counter in opening deals.
“The Intellectual Property Appellate Board (IPAB) has upheld the Compulsory License (CL) issued by the Controller of Patent to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation,” the Business Standard report suggests.
“The Appellate Board however made changes in the CL order to the extend that the royalty payment to Bayer has been increased from 6% to 7%. The Board also imposed a penalty on Natco for submitting false statement,” added report.
The order will pave the way for reduction in the prices of costly life saving drugs.The stock opened at Rs 449 and touched high of Rs 475 on NSE. A combined around 18,000 shares have changed hands on the counter in opening deals.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%